|Bid||4.3000 x 2000|
|Ask||5.0000 x 1000|
|Day's Range||4.5550 - 5.0550|
|52 Week Range||1.5100 - 6.2100|
|PE Ratio (TTM)||-2.87|
|Earnings Date||Apr 27, 2017 - May 1, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.23|
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that Mark Enyedy, president and chief executive officer, will present at the upcoming Jefferies 2017 Global Healthcare Conference in New York, NY.
Debiopharm International SA , part of Debiopharm Group™, a Switzerland-based biopharmaceutical company, and ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that Debiopharm has acquired ImmunoGen’s IMGN529/DEBIO 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas ...
ImmunoGen, Inc. (IMGN) shares jumped above 14% in the last trading session.